趙月
職稱:副主任醫(yī)師
科室:腫瘤介入科
學(xué)位/學(xué)歷:博士
導(dǎo)師資格:碩士生導(dǎo)師
簡(jiǎn)介:主要擅長(zhǎng)惡性腫瘤,,包括原發(fā)性肝癌,、轉(zhuǎn)移性肝癌,、膀胱癌,、胃腸道腫瘤、肺癌,、胰腺癌等的微創(chuàng)消融治療(微波消融,、射頻消融、冷凍消融),、介入化療栓塞(TACE),、藥盒置入、靶向治療,、免疫治療等綜合介入治療,,以及惡性膽道梗阻的支架植入,、腫瘤穿刺活檢等。
出診時(shí)間
專(zhuān)家門(mén)診
周一
Mon
周二
Tue
周三
Wed
周四
Thur
周五
Fri
周六
Sat
周日
Sun
上午
AM
下午
PM
出診時(shí)間以實(shí)際為準(zhǔn)

醫(yī)療特長(zhǎng):主要擅長(zhǎng)惡性腫瘤,,包括原發(fā)性肝癌,、轉(zhuǎn)移性肝癌、膀胱癌,、胃腸道腫瘤,、肺癌、胰腺癌等的微創(chuàng)消融治療(微波消融,、射頻消融,、冷凍消融)、介入化療栓塞(TACE),、藥盒置入,、靶向治療、免疫治療等綜合介入治療,,以及惡性膽道梗阻的支架植入,、腫瘤穿刺活檢等。

 

2016年畢業(yè)于中山大學(xué)臨床醫(yī)學(xué)八年制,,后于我院腫瘤介入科工作至今,。近年來(lái)主持國(guó)家自然科學(xué)基金1項(xiàng),廣東省自然科學(xué)基金項(xiàng)目3項(xiàng),,廣州市科技基礎(chǔ)與應(yīng)用基礎(chǔ)項(xiàng)目1項(xiàng),,中山大學(xué)教學(xué)質(zhì)量建設(shè)項(xiàng)目1項(xiàng),參與國(guó)家級(jí),、省部級(jí)等科研項(xiàng)目5項(xiàng),。共發(fā)表SCI論文20余篇,其中以第一/共一作者在J Clin Invest,、Cancer Res,、Mol Ther等國(guó)際高質(zhì)量雜志發(fā)表SCI 論文8篇,IF>10分3篇,。獲廣東省科技進(jìn)步二等獎(jiǎng)1項(xiàng),,授權(quán)專(zhuān)利5項(xiàng)。現(xiàn)任亞洲冷凍治療學(xué)會(huì)秘書(shū)兼委員,、廣東基層醫(yī)藥協(xié)會(huì)轉(zhuǎn)移性肝癌專(zhuān)業(yè)委員會(huì)委員,、廣東省抗癌協(xié)會(huì)神經(jīng)內(nèi)分泌腫瘤專(zhuān)業(yè)委員會(huì)委員等。

發(fā)表文章:

1. Zhao Y, Chen J, Zheng H, Luo Y, An M, Lin Y, Pang M, Li Y, Kong Yao, He Wang, Lin T, Chen C. SUMOylation-driven mRNA circularization enhances translation and promotes lymphatic metastasis of bladder cancer. Cancer Res. 2023 Nov 22; CAN-23-2278.

2. Zhu J, Luo Y, Zhao Y, Kong Y, Zheng H, Li Y, Gao B, Ai L, Huang H, Huang J, Li Z, Chen C. circEHBP1 promotes lymphangiogenesis and lymphatic metastasis of bladder cancer via miR-130a-3p/TGFbetaR1/VEGF-D signaling. Mol Ther 2021 MAY;29(5).

3. Chen C, Luo Y, He W, Zhao Y, Kong Y, Liu H, Zhong G, Li Y, Li J, Huang J, Chen R, Lin T. Exosomal long noncoding RNA LNMAT2 promotes lymphatic metastasis in bladder cancer. J Clin Invest 2020;130(1):404-421.

4 Chen C, Huang H, Zhao Y, Liu H, Luo Y, Sylvester RJ, Li JP, Lam TB, Lin T, Huang J Diagnostic accuracy of photodynamic diagnosis with 5-aminolevulinic acid, hexaminolevulinate and narrow band imaging for non-muscle invasive bladder cancer. J Cancer 2020;11:1082-1093.

5. Zhao Y, Huang H, Chen C, Liu H, Liu H, Su F, Bi J, Lam TB, Li J, Lin T, Huang J. Efficacy and safety of different interventions in castration resistant prostate cancer progressing after docetaxel-based chemotherapy: Bayesian network analysis of randomized controlled trials. J Cancer 2018;9:690-701.

6. Zhao Y, Chen C, Pan W, Gao M, He W, Mao R, Lin T, Huang J. Comparative efficacy of vitamin D status in reducing the risk of bladder cancer: A systematic review and network meta-analysis. Nutrition 2016;32:515-523.

7. Guo JL, Zhang DD, Zhao Y, Zhang D, Zhang XM, Zhou CQ, Yao SZ. Pharmacologic Interventions in Preventing Ovarian Hyperstimulation Syndrome: A Systematic Review and Network Meta-Analysis. Sci Rep 2016;6:19093.

8. Zhao Y, Chen B, He Y, Zhang S, Qiu Y, Feng R, Yang H, Zeng Z, Ben-Horin S, Chen M, Mao R. Risk Factors Associated with Impaired Ovarian Reserve in Young Women of Reproductive Age with Crohn's Disease. Intest Res 2020;18:200-209.